<?xml version="1.0" encoding="UTF-8"?>
<p id="Par55">Carboplatin and paclitaxel administration continued for at least 4 cycles, but could continue for up to 6 cycles at the investigator's discretion. Following completion of chemotherapy, patients who experienced a response (CR or PR) or had remained stable (SD) were eligible to continue on maintenance therapy receiving BTH1677/bevacizumab (BTH1677 arm) or bevacizumab (Control arm).</p>
